by Daniel X. Thomas
EP 3 121 274 B1 relates to a method for predicting responsiveness to the treatment of cancer with a compound inhibiting p300.
Brief outline of the case
The patent was revoked for lack of sufficiency for the patent as granted as well as for AR1-7. AR8 was not admitted by the OD.
by Daniel X. Thomas
EP 2 265 251 B1 relates to pharmaceutical compositions that contain surfactant concentrations that promote bioavailability of a therapeutic agent in the composition.
Brief outline of the case
In the course of first appeal proceedings, cf. T 2431/17, the opponents objected for the first time that the priority was invalid for lack of entitlement,